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Abstract: Objectives: Metastases in Meckel’s cave are a rare tumor entity, but they should 
be considered in patients with a known primary malignancy and who complain of 
trigeminal neuralgia. Methods: The case of a patient with a left trigeminal neuralgia 
caused by a metastatic tumor involving the Meckel’s cave and Gasserian ganglion is 
reported. Preoperative symptoms included headache, trigeminal hyperesthesia and facial 
pain. Results: The patient underwent microsurgical resection of the tumor, obtaining a 
histological diagnosis and a resolution of the pain. Trigeminal motor function was 
preserved. Conclusion: The best treatment for tumors of Meckel’s cave, including 
metastases, is complete microsurgical removal. Although good results have been 
reported with radiosurgery, this treatment should be reserved only for nonresectable and 
residual tumors. 
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Introduction 
Tumors of Meckel’s cave involving the 
Gasserian ganglion are usually benign and are 
either meningioma or trigeminal neurinomas 
(1,8). They represent less than 0.5% of all 
intracranial tumors (4). Patients can complain 
of a variety of symptoms, but most of them 
present with dysfunction of the fifth cranial 
nerve (14). 
Metastases in Meckel’s cave are a rare 
tumor entity and should be considered as 
important differential diagnosis, especially if 
the patient suffers from a known primary 
malignancy. We report the case of a patient 
with left atypical trigeminal neuralgia caused 
by a metastatic tumor that involved the 
Meckel’s cave. He was previously diagnosed 
with a pulmonary neoplasm. 
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Case report  
A 50 years old man presented with a six 
months history of burning and stabbing pain 
around the left infraorbital ridge and cheek. 
The pain was limited in the territory of the 
distribution of the trigeminal nerve. During 
the last month, the frequency and severity of 
episodes increased, without occasional 
spontaneous remissions as before. All the 
symptoms were unilateral. The patient had 
undergone several therapeutic attempts to 
control his pain. Previous treatment included 
dental extractions, diphenylhydantoin and 
carbamazepine administration. He had 
normal findings on physical examination, 
presenting no objective trigeminal motor loss, 
but a mild hyperesthesia in the left side of his 
face. 
Cerebral computerized tomography 
(Figure 1) showed a 3x2,5 cm. contrast 
enhancing lesion in Meckel’s cave on the left, 
without erosion of the apex of the petrous 
bone, but with little extension in the posterior 
fossa through the tentorial incisure. Axial T1-
weighted MRI with gadolinium enhancement 
(Figure 2) revealed a relatively well-defined 
mass in Meckel’s cave, with less peritumoral 
edema. The tumor uniformly enhanced 
gadolinium and extended to the left cavernous 
sinus without infiltrated it, and down to the 
cerebello-pontine angle. 
During his hospitalization, the patient was 
diagnosed, due to a preoperative chest 
radiography with a right lung lesion. We 
performed a contrast chest computed 
tomography which revealed a large right lung 
and a hilar mass, with smooth, lobulated 
margins, having around 10 cm. in the largest 
diameter (Figure 3). 
The patient underwent a left temporal 
craniotomy and a subtemporal intradural 
approach to the tumor. The craniotomy was 
enlarged to the base of the temporal fossa to 
obtain a flat viewing angle across the floor of 
the middle fossa. We performed a 
microsurgical complete resection of the 
supratentorial portion of the tumor, except for 
the portion that adhered to the inferior margin 
of the tentorial incisures (Figure 4). The 
tumoral mass intimately adhered to the dura 
mater that overlying the Meckel’s cave and 
Gasserian ganglion. It was debulked and its 
capsule was dissected from the dura (Figure 5). 
The dura mater was incised, but no extradural 
extension was noted. Without drilling the 
petrous apex we did not properly exposed the 
posterior fossa portion. 
The histological diagnosis was metastatic 
carcinoma with neuroendocrine 
differentiation (Figure 6). Postoperatively, the 
patient did well, but continued to have a partial 
fifth nerve dysfunction involving the second 
division. He presented episodic double vision, 
for the next two month, due to a mild sixth 
nerve paresis. 
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Figure 1 (a, b) - Preoperative axial contrast CT scan 
showed a relatively not well circumscribed tumor, 
with little peritumoral edema, which enhanced the 
contrast and extended down in the left cerebello-
pontine angle 
 
 
Figure 2 (a, b) – Axial T1-weighted images with 
gadolinium enhancement showed a 2,5x3 cm 
diameter tumor, with relatively uniform 
enhancement of gadolinium contrast, located in the 
left Meckel’s cave, extending to the left cavernous 
sinus without infiltrated it, and down to the 
cerebello-pontine angle 
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Figure 3 (a, b) - Nonenhanced CT scan of the chest 
showed a large right lung and a hilar mass, with 
smooth, lobulated margins, having around 10 cm. in 
the largest diameter, and extending right near the 
pleura 
 
 
 
Figure 4 (a, b) – Control native CT scan performed 6 
days after surgery. The rest of the tumor attached to 
the inferior margin of the tentorial incisura was 
noticed 
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Figure 5 (a, b) - Intraoperative images obtained 
under microscope during a subtemporal intradural 
approach. (a) – black arrows: tentorium; white 
arrow- microscopic aspect of the tumor overlying 
Meckel’s cave; (b) – black arrows: tentorium after 
removing the tumor over the gasserian ganglion; 
white arrow – the rest of the tumor extending 
inferiorly into the CPA 
Discussion 
The most common tumors in Meckel’cave 
are neurinomas and meningiomas (3, 4). 
Besides this two entities, other types of 
pathological lesions have been reported in the 
region of the gasserian ganglion: metastatic 
carcinomas, sarcomas, arteriovenous 
malformations and amyloidomas (2, 4). We 
presented the case of a patient harboring a 
metastatic tumor in the Meckel’s cave, who 
had been previously diagnosed with a lung 
primary malignancy. 
 
Figure 6 - Hystopathology of the tumour 
(Hematoxylin-Eosin):  metastatic carcinoma with 
neuroendocrine differentiation; typical 
histopathology includes nests of small primitive 
appearing cells with hyperchromatic nuclei, high 
nuclear to cytoplasmic ratio, mitotic figures and 
necrosis 
 
The incidence of brain metastases is 
difficult to determine with precision. In earlier 
neurosurgical series the overall incidence of 
cerebral metastases was 20%- 30% for all 
patients with systemic cancer (16). Estimates 
based on more recent series and autopsy 
studies show a much higher incidence of brain 
metastases, with incidences varying between 
8.3 and 11.1 per 100.000 individuals (11). 
Approximately 40% of intracranial neoplasms 
are metastatic (7). These estimates place brain 
metastases first in frequency among all 
intracranial tumors, before intracranial glioma 
and meningioma (26). 
The histological type of the primary tumor 
appears to be the major factor of the frequency 
and pattern of intracranial spread. Multiple, 
large autopsies series suggest that, in order of 
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decreasing frequency, lung, breast, melanoma, 
renal and colon cancer are the most common 
primary tumors that metastasize to brain (7, 
11, 26). Primary lung tumors account for 30% 
to 60% of all brain metastasis cases (8). Breast 
cancer ranks second, contributing 10% to 30% 
(12) of all brain metastases among women 
(19), and renal cancer has a frequency of 11% 
(24). When the ability of a primary tumor to 
spread to the brain is considered, melanoma 
ranks first followed by lung and breast cancers 
(7, 15). 
The first sign of a tumor of Meckel’s cave is 
usually that of trigeminal nerve dysfunction. 
Facial hypalgesia along the distribution of the 
trigeminal nerve is the most common 
symptom. This is usually constant and 
burning in nature. A diminish corneal reflex 
and motor involvement of the fifth cranial 
nerve usually follows. Not all tumors of the 
gasserian ganglion presented with pain. 
According to Jefferson (10), those tumors 
located in the posterior fossa, compressing the 
sensory root, are thought to be typically 
painless, with posterior fossa and pyramidal 
signs. In our case, the tumor had little 
extension down in the cerebello-pontine 
angle, most of it compressing the gasserian 
ganglion in the Meckel’s cave. That’s why our 
patient presented with stubbing facial pain and 
numbness, especially involving the second 
division of the trigeminal nerve, and no 
pyramidal signs were noticed. 
Computerized tomography (CT) and 
magnetic resonance imaging (MRI) permit the 
detection of small tumors in the region of 
Meckel’s cave. MRI study gives the best 
information concerning the localization and 
extent of the tumor in addition to revealing the 
displacement of neighboring structures and 
involvement of the cavernous sinus and vessels 
(20). Sometimes, the limits of the tumor were 
very indistinct on CT scan, and only the 
presence of bone erosion suggests a mass 
lesion (2). In low-density tumors, such as 
lipoma, epidermoid cyst or chordoma, 
magnetic resonance imaging was especially 
useful. In our case, axial MRI T1-weighted 
images with gadolinium enhancement showed 
a tumor, which enhances the contrast 
relatively uniform, located in the left Meckel’s 
cave, extending to the left cavernous sinus 
without infiltrated it, and down to the 
cerebello-pontine angle. Differential diagnosis 
must include meningiomas, neurinomas, 
epidermoid cysts, metastasis, chordomas, 
chondrosarcomas and maxillary sinus tumors 
(23). 
The surgical approach usually depends on 
the extent of the tumor. The main part of the 
tumor is located in the middle fossa but it may 
have extracranial extension or posterior fossa 
extension. These modifications are important 
to assure the best surgical approach for each 
type of lesion. These tumors can be resected 
via an extradural approach or an intradural 
approach. Most of them are extirpated via a 
middle fossa approach, either intradurally (for 
large lesions) or extradurally (for small 
lesions). The degree of difficulty in radical 
surgical removal depends on the particularities 
of each case, but, mainly, it depends on 
anatomical extension of the tumor. In order of 
their frequencies, the most used approaches 
are: middle fossa approach, retrosigmoid 
approach and presigmoid approach (20). The 
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last two approaches are especially used in the 
resection of tumors with important extension 
in the posterior fossa. In cases of small 
extranevraxial lesions, such as meningiomas 
and neurinomas, a safe surgery could be 
performed only by using an extradural 
approach (20, 23).  
The majority of tumors in Meckel’s cave 
location are amenable to be resected via the 
subtemporal intradural approach. 
Hyperventilation and intraoperative spinal 
drainage reduced brain bulk, and temporal 
bone retraction was minimal. The tumor could 
extend from Meckel’s cave to the superior 
orbital fissure and down to the cerebello-
pontine angle. The mass is usually well 
circumscribed and total removal can be 
achieved, leaving only remnants of capsule 
adherent to the fifth cranial nerve. Under 
microscope magnification, a dural opening 
must be made parallel to the tentorial edge in 
order to avoid cutting across fibers of the 
trigeminal nerve that lie directly beneath. Most 
of the tumors in this location are benign and 
can be totally resected. When flecks of capsule 
from the tumor is adherent to nerve fibers and 
brain stem, or is important extension in the 
CPA, attempts to remove the entire tumor 
would significantly increase the neurological 
deficits (5). For the rest of the tumor, 
fractioned radiation therapy is used. 
Using microsurgical techniques, the 
outcome of tumors involving Meckel’s cave 
and gasserian ganglion is usually favorable. 
The most frequent symptom after surgery is 
trigeminal hypesthesia, which is transient in 
most cases. Facial pain may persist after 
surgery, but most patients report 
improvement or total relief during follow-up. 
Patients who had experienced preoperative 
atypical trigeminal pain reported a resolution 
of their symptoms after surgery. Diplopia, CSF 
leak or even meningitis have been also 
described as possible complications (20, 21).  
Most new cranial nerve deficits present 
resolution within 4-6 months (22). Several 
contemporary series have demonstrated no 
deaths or major surgical complications with 
radical removal of tumors in the Meckel’s cave 
and gasserian ganglion (6, 21). 
For small, nonresectable and residual 
tumors, good results have been reported with 
radiosurgery (17, 18). Long-term follow-up of 
patients treated with this method is still 
needed to evaluate the exact role of the 
radiosurgery in the late control of these lesions 
(17, 18). 
Lesions in Meckel’s cave can have a varied 
and unusual presentation, as well as an 
assortment of pathology. Beside neurinomas 
and meningiomas, metastatic tumors have 
been reported occupying Meckel’cave and 
compressing gasserian ganglion. Metastatic 
involvement of the Meckel’s cave occurs either 
via hematogenous dissemination from distant 
metastatic or perineural spread from tumors 
of the head and neck. Very few cases of 
metastatic involvement of the Meckel’s region 
have been published. On a meta-analysis 
(2010) of malignant tumors involving this 
region, Soni RC et al. (23) found 20 cases, 
including theirs, of malignant involvement of 
Meckel’s cave described in the literature. Most 
primary neoplasm involved were: small cell 
lung cancer (2 cases), breast cancer (4 cases), 
adenocarcinoma of colon (2 cases), lymphoma 
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(4 cases), renal cell cancer (1 case) and 
folicullar thyroid cancer (1 case) (9, 13, 25). 
Conclusion 
Malignant lesions involving the structures 
of Meckel’s cave are uncommon and may 
present later in life compared to meningioma 
and schwannoma. We underline the 
importance to thoroughly investigate the 
patients early for a possible primary as well as 
metastases, in those patients found to present 
a lesion in Meckel’s cave. Moreover, it is 
difficult to distinguish metastatic tumors from 
benign tumors solely based on clinical or 
radiographic characteristics. We believe that 
the best treatment is microsurgical removal of 
the metastases, followed, when necessary, by 
fractioned radiation therapy for any rest of the 
tumor. 
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